We are live on
!
Find out more
Lazard Asset Management Portfolio holdings
AUM
$60.8B
1-Year Est. Return
22.47%
This Fund
S&P 500
This Quarter
Est. Return
-3.24%
1 Year Est. Return
+22.47%
3 Year Est. Return
+62.53%
5 Year Est. Return
+77.87%
10 Year Est. Return
+305.76%
AUM
$73.5B
AUM Growth
-$7.73B
(-9.5%)
Cap. Flow
-$10.4B
Cap. Flow
% of AUM
-14.12%
Top 10 Holdings %
Top 10 Hldgs %
24.14%
Holding
2,549
New
227
Increased
861
Reduced
712
Closed
243
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
PPL
PPL Corp
PPL
|
+$301M |
| 2 |
Estee Lauder
EL
|
+$252M |
| 3 |
Boeing
BA
|
+$251M |
| 4 |
Kenvue
KVUE
|
+$174M |
| 5 |
Fidelity National Information Services
FIS
|
+$166M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Johnson & Johnson
JNJ
|
+$547M |
| 2 |
Union Pacific
UNP
|
+$459M |
| 3 |
Pinnacle West Capital
PNW
|
+$203M |
| 4 |
Wells Fargo
WFC
|
+$199M |
| 5 |
Bank of America
BAC
|
+$199M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.75% |
| 2 | Healthcare | 13.74% |
| 3 | Financials | 13.36% |
| 4 | Industrials | 11.58% |
| 5 | Consumer Discretionary | 9.22% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1901
Utz Brands
UTZ
$2.04B
| $19K | ﹤0.01% |
1,450
-351,258
| -100% | -$5.41M |
|
1902
Aecom
ACM
$9.63B
| $18K | ﹤0.01% |
226
-6
| -3% | -$517 |
|
1903
Kaltura
KLTR
$259M
| $18K | ﹤0.01% |
10,707
+1,116
| +12% | +$2.2K |
|
1904
Red Violet
RDVT
$950M
| $18K | ﹤0.01% |
+941
| New | +$19.5K |
|
1905
Allogene Therapeutics
ALLO
$680M
| $17K | ﹤0.01% |
5,749
+250
| +5% | +$1.1K |
|
1906
Cullen/Frost Bankers
CFR
$10.2B
| $17K | ﹤0.01% |
195
| – | – |
|
1907
Embecta
EMBC
$208M
| $17K | ﹤0.01% |
1,132
-1,327
| -54% | -$24.9K |
|
1908
First Merchants
FRME
$2.69B
| $17K | ﹤0.01% |
647
| – | – |
|
1909
Magna International
MGA
$18.1B
| $17K | ﹤0.01% |
+321
| New | +$18.7K |
|
1910
Principal Financial Group
PFG
$24.7B
| $17K | ﹤0.01% |
240
| – | – |
|
|
TGI
1911
DELISTED
Triumph Group
TGI
| $17K | ﹤0.01% |
+2,332
| New | +$22.8K |
|
1912
TransUnion
TRU
$15.2B
| $17K | ﹤0.01% |
250
| – | – |
|
1913
Iovance Biotherapeutics
IOVA
$2.77B
| $16K | ﹤0.01% |
3,681
+146
| +4% | +$953 |
|
1914
Janux Therapeutics
JANX
$982M
| $16K | ﹤0.01% |
+1,667
| New | +$19.2K |
|
1915
Manulife Financial
MFC
$74.1B
| $16K | ﹤0.01% |
921
| – | – |
|
1916
Vir Biotechnology
VIR
$1.48B
| $16K | ﹤0.01% |
1,799
+542
| +43% | +$7.73K |
|
|
GMDA
1917
DELISTED
Gamida Cell Ltd. Ordinary Shares
GMDA
| $16K | ﹤0.01% |
16,679
+670
| +4% | +$856 |
|
|
ADVM
1918
DELISTED
Adverum Biotechnologies
ADVM
| $15K | ﹤0.01% |
1,049
+43
| +4% | +$772 |
|
1919
Axalta
AXTA
$8.03B
| $15K | ﹤0.01% |
576
| – | – |
|
1920
Nathan's Famous
NATH
$403M
| $15K | ﹤0.01% |
213
| – | – |
|
1921
Prime Medicine
PRME
$533M
| $15K | ﹤0.01% |
1,670
+66
| +4% | +$857 |
|
1922
Red Robin
RRGB
$156M
| $15K | ﹤0.01% |
1,949
| – | – |
|
1923
Fresenius Medical Care
FMS
$12.8B
| $14K | ﹤0.01% |
+671
| New | +$16.3K |
|
1924
Roku
ROKU
$22.3B
| $14K | ﹤0.01% |
200
+188
| +1,567% | +$14.6K |
|
|
SGEN
1925
DELISTED
Seagen Inc. Common Stock
SGEN
| $14K | ﹤0.01% |
69
+56
| +431% | +$11.2K |
|
Similar funds
QCM
Lazard Asset Management's Q3 2023 Portfolio in Review
As of Q3 2023, Lazard Asset Management held 2,549 positions worth $73.5B, down 9.5% from $81.2B the previous quarter. Its ten largest holdings account for 24% of the portfolio.
Lazard Asset Management withdrew a net $10.4B in Q3 2023, closing 243 positions and reducing 712 holdings. Its most notable exit was Littelfuse, an estimated $24.3M position sold in full.
By sector, the portfolio is most concentrated in Technology at 20% of assets, up from 20% a quarter earlier, followed by Healthcare and Financials.
Against the trend, Lazard Asset Management opened a new position in ScottsMiracle-Gro worth $28.3M.
- Lazard Asset Management's largest Q3 2023 buy was ScottsMiracle-Gro: 548,310 shares worth $28.3M.
- Lazard Asset Management added most to PPL Corp in Q3 2023, an estimated $301M increase.
- Lazard Asset Management's biggest Q3 2023 reduction was Johnson & Johnson, cutting an estimated $547M.
- Lazard Asset Management fully exited Littelfuse in Q3 2023, selling an estimated $24.3M.
- Lazard Asset Management's ten largest holdings make up 24% of its $73.5B portfolio in Q3 2023.
- Lazard Asset Management opened 227 new positions and closed 243 in Q3 2023.
- Lazard Asset Management's portfolio value fell 9.5% quarter-over-quarter to $73.5B.
Based on Lazard Asset Management's 13F filing for Q3 2023, filed 14 Nov 2023.